Abstract: This invention relates to N-hydroxy-dibenz?b,e!oxepinalkylamines, N-hydroxy-dibenz?b,e!oxepinalkanoic acid amides and related heterocyclic analogues of the formula ##STR1## where X together with the carbon atoms to which it is attached forms a benzene or thiophene ring; W and Z are independently hydrogen, halogen, loweralkyl, or trifluoromethyl; R.sup.1 is hydrogen, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; R.sup.2 is loweralkyl, cycloalkyl, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; m is 0 or 1 and n is an integer of 0 to 4 or the pharmaceutically acceptable salts thereof. The compounds of this invention are useful as analgesics and topical antiinflammatory agents for the treatment of various dermatoses and agents for the treatment of conditions where accumulation of cyclooxygenase and/or lipoxygenase metabolites is a causative factor.
Type:
Grant
Filed:
February 27, 1998
Date of Patent:
June 29, 1999
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Richard C. Allen, Grover C. Helsley, R. Richard L. Hamer, Brian S. Freed, John I. White, Lawrence L. Martin
Abstract: Novel carbamoyloxylabdanes, intermediates and processes for the preparation thereof, and methods for reducing intraocular pressure and treating cardiac failure utilizing compounds and compositions thereof are disclosed.
Type:
Grant
Filed:
January 8, 1997
Date of Patent:
February 9, 1999
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Raymond W. Kosley, Jr., Robert Joseph Cherill, Gerard O'Malley
Abstract: This invention relates to the treatment of depression by administration of novel 3-(R.sub.n -phenyl)-1,4-dialkyl-1,2,4-triazolium salts of the formula ##STR1## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl or C.sub.1-4 lower alkoxy,n is zero, 1 or 2, andR.sub.1 and R.sub.4 independently represent C.sub.1-3 lower alkyl;and A.sup.- represents a pharmaceutically acceptable anion.
Type:
Grant
Filed:
December 13, 1996
Date of Patent:
January 5, 1999
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Christopher Robin Dalton, John Michael Kane, John Herr Kehne
Abstract: Novel carbamoyloxylabdanes, intermediates and processes for the preparation thereof, and methods for reducing intraocular pressure and treating cardiac failure utilizing compounds and compositions thereof are disclosed.
Type:
Grant
Filed:
June 30, 1997
Date of Patent:
December 8, 1998
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Raymond W. Kosley, Jr., Robert Joseph Cherill, Gerard O'Malley
Abstract: Herein is described an ocular composition comprising an ocular decongestant such as phenylephrine and certain labdane derivatives which are intraocular pressure lowering agents. The composition not only markedly reduces the ocular reddening otherwise produced by such labdane compounds, but also unexpectedly prolongs and frequently potentiates their intraocular pressure lowering effect. Both of these effects are very beneficial to the use of such labdanes for the treatment of glaucoma.Also described herein is an ocular composition comprising para-aminoclonidine (an .alpha..sub.2 -adrenoreceptor agonist) and certain labdane derivatives mentioned above. The composition reduces the ocular reddening and lacrimation, and also potentiates the intraocular pressure lowering effect.
Type:
Grant
Filed:
March 6, 1997
Date of Patent:
December 8, 1998
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Paul Gary Conway, Grover Cleveland Helsley, Joachim Eggert Roehr
Abstract: This invention relates to N-hydroxy-dibenz?b,e!oxepinalkylamines, N-hydroxy-dibenz?b,e!oxepinalkanoic acid amides and related heterocyclic analogues of the formula ##STR1## where X together with the carbon atoms to which it is attached forms a benzene or thiophene ring; W and Z are independently hydrogen, halogen, loweralkyl, or trifluoromethyl; R.sup.1 is hydrogen, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; R.sup.2 is loweralkyl, cycloalkyl, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; m is 0 or 1 and n is an integer of 0 to 4 or the pharmaceutically acceptable salts thereof. The compounds of this invention are useful as analgesics and topical antiinflammatory agents for the treatment of various dermatoses and agents for the treatment of conditions where accumulation of cyclooxygenase and/or lipoxygenase metabolites is a causative factor.
Type:
Grant
Filed:
March 8, 1994
Date of Patent:
November 24, 1998
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Richard C. Allen, Grover C. Helsley, R. Richard L. Hamer, Brian S. Freed, John I. White, Lawrence L. Martin
Abstract: This application relates to compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined within, which compounds are useful for the treatment of memory dysfunction characterized by decreased cholinergic function, pharmaceutical compositions containing the compounds and methods for making and using the compounds.
Type:
Grant
Filed:
May 22, 1995
Date of Patent:
July 7, 1998
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Raymond W. Kosley, Jr., Larry Davis, Veronica Taberna
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
July 29, 1997
Date of Patent:
June 23, 1998
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
December 9, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
November 11, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
November 11, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
November 11, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
November 4, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes of the formula ##STR1## wherein: a. X is hydrogen, loweralkyl, loweralkoxy, halogen, trifluoromethyl, or a group of the formula ##STR2## wherein Y is hydrogen or loweralkyl, and p is 1 or 2; b. A is a group of the formula ##STR3## c. R.sup.1 and R.sup.2 are independently hydrogen or lowerakyl; and d. m is 2 to 6 and n is 0, or 2 to 6, inclusive, serotonin reuptake inhibitors, useful for treating depression and obsessive compulsive disorders are described. Also described are precursors of and processes for the preparation of such aminoakyloximes.
Type:
Grant
Filed:
August 3, 1994
Date of Patent:
September 9, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
July 15, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Gregory M. Shutske, Brian S. Freed, John D. Tomer, IV, R. Richard L. Hamer
Abstract: This invention relates to neuroprotective 5-aryl-3H-1,2,4-triazol-3-ones and to their use in the treatment of neurodegenerative disorders such as cerebral ischemia, stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Type:
Grant
Filed:
March 15, 1990
Date of Patent:
July 25, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Stephen M. Sorensen, John M. Kane, Francis P. Miller
Abstract: 2,3-Dihydro-1-(8-methyl-1,2,4-triazolo [4,3-b]pyridazin-6-yl)-4(1H)-pyridinone has been prepared in substantially pure form and has been found to be useful for alleviating bronchial spasms in mammals. Synthesis of this material through phenylselenyl intermediates is described.
Abstract: This invention relates to the enhancement of memory and cognition and the treatment of Alzheimer's disease and Wernicke-Korsakoff syndrome by administration of 5-(R.sub.n -phenyl)-4-alkyl-3H-1,2,4-triazole-3-thiones of the formula ##STR1## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl orC.sub.1-4 lower alkoxy,n is zero, 1 or 2, andR.sub.2 represents hydrogen or C.sub.1-3 lower alkyl; andR.sub.4 independently represents C.sub.1-3 lower alkyl.
Abstract: This invention relates to the enhancement of memory and cognition and the treatment of Alzheimer's disease by administration of 5-(R.sub.n -phenyl)-4-alkyl-3H-1,2,4-triazole-3-thiones of the formula ##STR1## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl or C.sub.1-4 lower alkoxy,n is zero, 1 or 2, andR.sub.2 represents hydrogen or C.sub.1-3 lower alkyl; andR.sub.4 independently represents C.sub.1-3 lower alkyl.
Abstract: The use of 1-(thienylalkyl)imidazole-2-thione derivatives as antihyperthyroid agents are described herein. These compounds may be administered as a preparatory adjunct procedure when thyroidectomy or radioactive iodine therapy is the recommended therapy or as a primary therapy when surgical procedures is not recommended or long term therapy is advisabe.